Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Endocrine 1

Conditions

Neuroendocrine Tumors 3Thyroid Neoplasms 2Thyroid Carcinoma, Anaplastic 2Zollinger-Ellison Syndrome 1Thyroid Cancer, Papillary 1Somatostatinoma 1Pheochromocytoma 1Paraganglioma, Extra-Adrenal 1Paraganglioma 1Multiple Endocrine Neoplasia Type 1 1Insulinoma 1Glucagonoma 1Carcinoma, Medullary 1Adenocarcinoma, Follicular 1

Interventions

Temozolomide 2Capecitabine 2veliparib 1pazopanib 1cixutumumab 1Salts 1Octreotide 1Lansoprazole 1Everolimus 1Acetates 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Zollinger-Ellison Syndrome × pazopanib × Endocrine × Clear all
NCT00454363 2020-04-03

Pazopanib Hydrochloride in Treating Patients With Advanced Neuroendocrine Cancer

National Cancer Institute (NCI)

Phase 2 Completed
52 enrolled 11 charts
Endocrine

Glucagonoma, Insulinoma, Somatostatinoma, Zollinger-Ellison Syndrome, Multiple Endocrine Neoplasia Type 1

Data powered by HemOnc (CC BY 4.0) Colophon âš¡